Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease

Supported by an unrestricted educational grant from AstraZeneca

Chairperson: P. Steg

Panellists: D. Angiolillo, C. Cook

Summary

Consult this session to learn more about the cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease, and the clinical strategy for treatment implementation.

Learning Objectives

To review the improved cardiovascular outcomes with new antidiabetic drugs
To discuss the clinical strategy for treatment implementation

Presentations available when logged in:

Case presentation
How did I treat?
Impact of new antidiabetic drugs on cardiovascular outcomes

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease

Supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

Log in or create account for free